- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04709900
CT Stress myokardieperfusion, fraktionel flowreserve og angiografi hos patienter med stabile brystsmertesyndromer (DYNAMITE)
DYNAMISK CT-stress myokardieperfusion, CT-fraktionel flowreserve og koronar CT-angiografi til optimeret behandlingsstrategi hos patienter med stabile brystsmertesyndromer
The purpose of the DYNAMITE trial (Dynamic CT stress myocardial perfusion, CT fractional flow reserve (FFR-CT) and coronary CT angiography for optimized treatment strategy in patients with chest pain syndromes) is to determine the ability of combined anatomical and functional cardiac CT imaging to improve morbidity and mortality in patients with suspected or known ischemic heart disease.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Trial design
The DYNAMITE trial is an investigator-initiated, randomised controlled, open-labelled trial conducted in the Capital Region of Copenhagen, Denmark
The following hypothesis will be tested:
- First primary hypothesis: A treatment strategy guided by combined dynamic CT myocardial stress perfusion, FFR-CT and CT coronary angiography improves clinical outcome compared with a conventional management strategy in patients with chronic chest pain syndromes
- Second primary hypothesis: A treatment strategy guided by combined dynamic CT stress myocardial perfusion, FFR-CT and CT coronary angiography results in improved symptom relief compared with a conventional management strategy in patients with chronic chest pain syndromes
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Klaus F Kofoed, MD
- Telefonnummer: 004535458569
- E-mail: Klaus.kofoed@regionh.dk
Studiesteder
-
-
-
Copenhagen, Danmark, 2100
- Rekruttering
- Department of Cardiology and Radiology, Rigshospitalet, The Heart Center, Capital Region of Copenhagen, University of Copenhagen
-
Kontakt:
- Klaus F Kofoed, MD, DmSc
- Telefonnummer: +45 35458569
- E-mail: Klaus.kofoed@regionh.dk
-
Underforsker:
- Jesper J Linde, MD, Ph.D
-
Underforsker:
- Lars V Køber, MD,DmSc
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Chest pain in patients with clinically suspected or confirmed ischemic heart disease
-
Clinical indication for non-acute coronary evaluation
-
Status of coronary revascularization
-
With previous coronary revascularization - all patients
-
Without previous coronary revascularization
-
Age≥65 years - all patients with chest pain
-
Age>50 - <65 years - typical angina pectoris and at least one cardiovascular risk factor and/or previous myocardial infarction
- Typical angina requiring all 3 criteria present: a) constrictive discomfort in the front of the chest or in the neck, jaw, shoulder or arm, b) precipitated by physical exertion c) relieved by rest or nitrates within 5 min.
- Cardiovascular risk factors: hypertension, diabetes, hypercholesterolemia, current smoking, family history of ischemic heart disease, previous stroke, peripheral artery disease
-
-
Exclusion Criteria:
- Persistent chest pain and signs of ongoing acute myocardial ischemia requiring acute coronary intervention
- Hospitalization and discharge with the confirmed diagnosis acute coronary syndrome (STEMI or NSTEMI) within the last 6 months
- Severe valvular heart disease as primary diagnosis and/or in potential need of percutaneous or surgical valve treatment
- Known severe heart failure (LVEF less than 35%)
- Language, cultural or mental factors preventing the patient from understanding the informed consent form
- Known atrial fibrillation
- Known renal impairment (estimated Glomerular Filtration Rate below <30 ml/min)
- Known x-ray contrast allergy
- Known intolerance to adenosine infusion
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Intervention group
CT angiography, FFR-CT and dynamic CT stress myocardial perfusion guided treatment strategy |
The study intervention team consists of a specialist in Cardiac CT imaging, an invasive cardiologist, a thoracic surgeon and a cardiology nurse specialist. Treatment strategy defined by the study team based on CT findings involve referral for percutaneous coronary intervention, Coronary Artery Bypass surgery and/or initiation of optimal medical therapy, in addition to potential supplementary diagnostic procedures. |
|
Ingen indgriben: Standard care group
Evaluation and treatment strategy according to contemporary clinical practice |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Major Adverse Cardiovascular Events
Tidsramme: 3 years
|
cardiovascular death, acute myocardial infarction, stroke or hospitalization for heart failure |
3 years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Individual components of the primary endpoint
Tidsramme: 3 years
|
cardiovascular death; acute myocardial infarction; stroke or hospitalization for heart failure |
3 years
|
|
Acute myocardial infarction stratified by subtype
Tidsramme: 12 months
|
Subtypes of acute myocardial infarction according to Fourth Universal Definition 2018 |
12 months
|
|
Hospitalization due to unstable angina pectoris, bleeding, pacemaker and/or implantable/cardioverter defibrillator implantation, surgical or percutaneous heart valve treatment
Tidsramme: 3 years
|
Cardiovascular hospitalizations |
3 years
|
|
All-cause mortality
Tidsramme: 3 years
|
All-cause mortality |
3 years
|
|
All-cause mortality
Tidsramme: 10 years
|
Long-term registry based all-cause mortality at 10 years |
10 years
|
|
Number and type of diagnostic tests performed
Tidsramme: 12 months
|
Cardiac CT, Exercise ECG, perfusion Positron Emission Tomography, perfusion Single-photon emission computed tomography, perfusion magnetic resonance, invasive coronary angiography, invasive fractional flow reserve, intravascular ultrasound, optical coherence tomography |
12 months
|
|
Number of invasive coronary test not leading to coronary revascularization
Tidsramme: 12 months
|
number of invasive procedures |
12 months
|
|
Number of coronary revascularization
Tidsramme: 3 years
|
Coronary bypass surgery and/or percutaneous coronary intervention |
3 years
|
|
Cumulative iodinated contrast volume
Tidsramme: 12 months
|
Cardiac computed tomography, invasive coronary angiography, invasive fractional flow reserve, intravascular ultrasound, invasive optical coherence tomography |
12 months
|
|
Cumulative radiation dose
Tidsramme: 12 months
|
Cardiac CT, perfusion Positron Emission Tomography, perfusion Single-photon emission computed tomography, perfusion magnetic resonance, invasive coronary angiography, invasive fractional flow reserve, intravascular ultrasound, optical coherence tomography |
12 months
|
|
Major procedural complications occuring during procedures (invasive, non-invasive or coronary revascularization)
Tidsramme: 12 months
|
death, cardiac arrest, cardiac arrhytmia, acute myocardial infarction, stroke, bleeding, unplanned revascularization and any complication requiring and/or prolonging hospitalizaation at least 24 hours |
12 months
|
|
Minor procedural complication specific to type of procedure (invasive, non-invasive or during coronary revascularization)
Tidsramme: 12 months
|
Minor procedural complications |
12 months
|
|
Patients diagnosed with non-cardiac disease as likely explanation for symptoms
Tidsramme: 12 months
|
non-cardiac diseases causing chest pain |
12 months
|
|
Seattle Angina Questionaire
Tidsramme: 3 months and 12 months
|
Seattle Angina Questionaire pre-randomization, 3 months and 12 months after randomization |
3 months and 12 months
|
|
Quality of life by EQ-5D-5L instrument
Tidsramme: 3 months and 12 months
|
Quality of life estimated by EQ-5D-5L instrument pre-randomization, 3 months and 12 months after randomization |
3 months and 12 months
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Klaus F Kofoed, MD, Department of Cardiology, Rigshospitalet, University of Copenhagen, Denmark
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Smerte
- Neurologiske manifestationer
- Cerebrovaskulære lidelser
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Karsygdomme
- Hjertesygdomme
- Åreforkalkning
- Arterielle okklusive sygdomme
- Koronar sygdom
- Myokardieiskæmi
- Patologiske tilstande, tegn og symptomer
- Tegn og symptomer
- Slag
- Hjertefejl
- Hjerte-kar-sygdomme
- Koronararteriesygdom
- Brystsmerter
- Diagnostiske teknikker og procedurer
- Diagnose
- Tomografi
- Diagnostisk billeddannelse
- Radiografi
- Billedtolkning, computerassisteret
- Radiografisk billedforbedring
- Billedforbedring
- Fotografering
- Tomografi, røntgenbillede
- Tomografi, røntgenbillede
- Multimodal billeddannelse
- Computed Tomography Angiography
Andre undersøgelses-id-numre
- NNF19OC0057592
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Following publication of the main results of the trial, anonymized data will be made available to other researchers through the Zenodo open data repository.
IPD-delingstidsramme
Statistical Analysis Plan and study protocol a time of publication
IPD-delingsadgangskriterier
Curated by principle investigator according to contemporary law
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .